Matinas BioPharma Holdings, Inc.
(NYSE Amex Equities : MTNB)

( )
MTNB PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-1.31%85.371.3%$1334.67m
AMGNAmgen Inc.
0.00%201.561.2%$603.80m
GILDGilead Sciences, Inc.
0.00%68.250.9%$535.10m
LOXOLoxo Oncology Inc
-0.03%233.7012.7%$517.58m
BIIBBiogen Inc.
-0.51%337.221.3%$412.55m
VRTXVertex Pharmaceuticals Incorporated
-2.06%189.891.9%$326.56m
ILMNIllumina, Inc.
0.53%303.893.5%$304.82m
REGNRegeneron Pharmaceuticals, Inc.
-0.88%401.212.6%$300.94m
ALXNAlexion Pharmaceuticals, Inc.
0.92%118.082.0%$225.36m
EXASExact Sciences Corporation
4.79%79.7125.3%$149.33m
AAgilent Technologies, Inc.
0.45%71.641.5%$147.28m
INCYIncyte Corporation
2.23%76.882.5%$147.19m
SRPTSarepta Therapeutics, Inc.
-1.30%118.7215.4%$129.31m
LGNDLigand Pharmaceuticals Incorporated
-1.00%111.7823.1%$119.93m
NBIXNeurocrine Biosciences, Inc.
-2.15%89.325.1%$95.56m

Company Profile

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its LNC platform technology. The company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its lead anti-fungal product candidate, MAT2203, delivers broad-spectrum fungicidal agent, amphotericin B; and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded in May 2013 and is headquartered in Bedminster, NJ.